US2018021170A1PendingUtilityA1

Implants with controlled drug delivery features and methods of using same

60
Assignee: DOSE MEDICAL CORPPriority: Mar 15, 2013Filed: Feb 16, 2017Published: Jan 25, 2018
Est. expiryMar 15, 2033(~6.7 yrs left)· nominal 20-yr term from priority
A61F 2250/0067A61F 9/0017A61F 9/00781
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Claims

exact text as granted — not AI-modified
1 . A drug delivery ocular implant comprising:
 an outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen;   at least a first active drug positioned within said interior lumen;   a cap configured for reversible interaction with the proximal end of said outer shell,
 wherein said cap comprises at least one aperture; 
   a membrane positioned between said cap and said proximal end of said outer shell,
 wherein said membrane is permeable to said at least a first active drug, 
 wherein said membrane is dimensioned based on the permeability of said membrane to said at least a first active drug and the desired duration of elution of said first active drug, 
 wherein upon placement of the cap over the proximal end of the outer shell, said membrane is retained between said cap and said proximal end, 
 wherein said membrane occludes said at least one aperture, thereby allowing elution of said at least a first active drug to occur only through said membrane; 
   at least one fluid inflow pathway and one fluid outflow pathway positioned adjacent the distal end of said outer shell,
 wherein said at least one fluid inflow pathway and one fluid outflow pathway are configured to deliver ocular fluid to a physiological outflow pathway; and 
   a retention protrusion on the distal end of said outer shell, wherein said retention protrusion is configured to anchor the ocular implant at a target tissue site.   
     
     
         2 .- 49 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.